Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Post by forhandlarenon Jun 14, 2022 2:58pm
253 Views
Post# 34755900

The prc PARTNERS interview

The prc PARTNERS interviewprc PARTNERS is a shareholder as everyone else? Or maybe not!

I think they were given information pre-deal based on:
- the interview is very polished - I like it, but very hard to accomplish in one day
- getting hold of three key management resources during the ongoing conference?
- the reference to share price close Friday June 10th on investment highlights

That raises the question of they bought shares based on in-the-know pre-deal?!

It also suggest that the close relationship indicates that the numbers published by prc PARTNERS pre- and post-deal are related to the real world. Could of course be debated.Was it $20M upfront?


Nevertheless, there are interesting breadcrumbs:
- AbbVie seems to already have started the product development which is very positive of course
- animal health deal expected to be closed this autumn
- upfront is invested in accelerated development
- $40M royalty equals about 1.86 CAD per share at P/E 10 and 275M shares - does prc PARTNERS speculate or are they in-the-know? Doesn't really matter as the numbers seems realistic anyway.


Sirona Biochem states on Twitter that "There are many more news to come in the next days" - does it refer to the post-deal interview or something else? I would be very surprised if there's more to bring to the market this week given the prc PARTNERS interview that covers a lot.
<< Previous
Bullboard Posts
Next >>